Skip to main content
OpenTrials
Completed

NCT Number: NCT05222022

Engineering Evaluation of an Eye Movement Monitor Device

The objective of the engineering evaluation is to verify and validate the design of an eye movement monitor device, the Retitrack, for recording, viewing, measuring, and analyzing temporal characteristics of fixation and saccadic responses in human eyes when viewing a visual stimulus.

This engineering evaluation is not an applicable clinical trial. This is a design validation of the mechanism of action of the device to measure eye movement. This is not a clinical trial to evaluate the effect of an intervention on biomedical or other health-related outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Blur Product Development

Cary, North Carolina, 27513, United States

About this study

This non-significant risk device evaluation involves obtaining retinal images and eye movement measurements with the Retitrack device for purposes of design verification and validation testing. These measurements are not intended for use in diagnosing, preventing, monitoring, or alleviating a medical condition. This evaluation is not intended to assess biomedical or other health-related outcomes.

The evaluation involves the voluntary participation of up to 40 healthy adults who participate in a single device testing visit conducted over one or two days. The Retitrack is used to assess the alignment of the eye for image capture, the ability to measure and analyze eye movements for fixational and visually guided saccadic responses, and the usability of the device.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • History of good health
  • Willing to participate in testing over 1 to 2 days with rest periods
  • Willing to participate in device testing involving viewing visual targets, moving eyes as directed, and holding head steady
  • Willing to have retinal images recorded for eye movement measurements

Exclusion criteria

  • Refractive correction with glasses or contact lenses of more than 12 diopters of myopia or 4 diopters of hyperopia in either eye
  • Active eye disease in either eye
  • History of ocular surgery or ocular trauma in either eye within the past three months
  • Ocular conditions in either eye that could interfere with obtaining a clear retinal image
  • Ocular conditions in either eye that could affect the ability to view a stimulus or limit eye movement
  • Neurological conditions that could affect eye movements

Treatment and study plan

Retitrack

Device

Retitrack device measures and analyzes eye movement

Primary outcomes

  1. Device measurement of involuntary fixational microsaccade amplitude

    Time frame: 1 day (Single timepoint)

    Microsaccade amplitude (in degrees)

  2. Device measurement of involuntary fixational microsaccade velocity

    Time frame: 1 day (Single timepoint)

    Microsaccade velocity (in degrees/second)

  3. Device measurement of visually guided horizontal saccade amplitude

    Time frame: 1 day (Single timepoint)

    Horizontal saccade amplitude (in degrees)

  4. Device measurement of visually guided horizontal saccade velocity

    Time frame: 1 day (Single timepoint)

    Horizontal saccade velocity (in degrees/second)

Sponsors and collaborators

Lead sponsor

C. Light Technologies, Inc.

Industry

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Feb 3, 2022
Registry last updated
Feb 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.